Brief: Ayala Pharmaceuticals posts Q2 EPS USD -1.82
10/08/2023 21:45
Aug 10 (Reuters) - Ayala Pharmaceuticals Q2 net income USD -8.699 million. * Q2 EPS USD -1.82 * Q2 operating income USD -8.486 million * Q2 pretax profit USD -8.572 million * Q2 collaboration revenue USD 9 thousand * Q2 basic EPS USD -1.82
Recent news on Ayala Pharmaceuticals
See all newsBrief: Ayala Pharmaceuticals Completes Sale Of AL102 To Immunome
Immunome slides on $200 mln equity offering
Immunome edges up after $200 mln equity offering
Brief: Immunome To Acquire AL102 Phase 3 Asset for the Treatment of Desmoid Tumors From Ayala Pharmaceuticals
Brief: Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors